S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
Ponatinib Background and Initial Approval
Elias Jabbour reviews ponatinib's approval, 45 mg starting dose, efficacy in heavily pretreated CML, and T315I activity.
Play episode from 04:48
Transcript
